Related Experiment Video
Updated: Jul 19, 2025
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
[Expression and Prognostic Value of Cytokines in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma]
Yan Man1, Chuan-Qin Ge1, Zeng-Zheng Li1
1Department of Hematology, The Affiliated Hospital of Kunming University of Science and Technology, The First People's Hospital of Yunnan Province, Kunming 650500, Yunnan Province, China.
Insights
High serum interleukin-10 (IL-10) levels in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients indicate a worse prognosis. Elevated IL-10 correlates with inflammation and tumor burden, predicting higher early mortality.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Context:
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
- Cytokines play a crucial role in immune response and cancer progression.
- Understanding prognostic markers is vital for managing DLBCL.
Purpose:
- To investigate the expression and prognostic significance of serum cytokines in newly diagnosed DLBCL patients.
- To determine the relationship between cytokine levels and patient survival outcomes.
Summary:
- Serum interleukin-10 (IL-10) was the only cytokine significantly differing between survival groups in 62 DLBCL patients.
- Elevated IL-10 levels (>11.74 pg/ml) correlated with higher lactate dehydrogenase (LDH) and indicated increased inflammation.
- Patients with high IL-10 exhibited significantly lower 3-year progression-free survival (PFS) and overall survival (OS) rates.
Impact:
- Serum IL-10 can serve as a prognostic biomarker for DLBCL, reflecting inflammatory status and tumor load.
- High IL-10 levels identify DLBCL patients at higher risk of early mortality and poorer outcomes.
- This finding may guide risk stratification and treatment decisions in DLBCL management.
Objective:
To investigate the expression and prognostic value of cytokines in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Methods:
Clinical data of 62 patients diagnosed with DLBCL in the First People's Hospital of Yunnan Province from June 2017 to November 2018 were collected. The differences in expression levels of 14 serum cytokines [interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-17F, IL-22, interferon (IFN)-γ, tumor necrosis factor (TNF)-α, TNF-β] in patients with different survival outcomes, and the impact of the cytokines on 3-year progression-free survival (PFS) and 3-year overall survival (OS) of patients with DLBCL were analyzed retrospectively.
Results:
Among the 14 cytokines, only the expression of IL-10 was significantly different in patients with different survival outcomes (P =0.007). According to the receiver operating characteristic (ROC) curve, the optimal cut-off value for IL-10 was 11.74 pg/ml. Serum IL-10 was positively correlated with infection markers procalcitonin (PCT) (r =0.321, P =0.029), C-reactive protein (CRP) (r =0.320, P =0.013) and tumor burden index lactate dehydrogenase (LDH) (r =0.439, P <0.001) in newly diagnosed DLBCL patients. The level of IL-10 in patients with pulmonary infection was significantly higher than that in patients without pulmonary infection (P =0.012). However, there was no statistically significant difference on the 3-year survival outcomes between patients with or without pulmonary infection. There was no significant difference in IL-10 level in patients with different Ann Arbor stages (P >0.05). Patients with high IL-10 level (IL-10>11.74 pg/ml) had significantly higher LDH level than those with low IL-10 level (IL-10≤11.74 pg/ml) (P <0.001). The 3-year PFS rate and 3-year OS rate of DLBCL patients with high IL-10 level were significantly lower than those of low IL-10 level group [(44.4±11.7)% vs (81.8±5.8)%, P <0.001; (61.6±11.5)% vs (93.2±3.8)%, P =0.001].
Conclusion:
Serum IL-10 level in newly diagnosed DLBCL patients can reflect the inflammatory state of the body, which may be related to tumor load. Newly diagnosed DLBCL patients with serum IL-10>11.74 pg/ml have higher early mortality and worse prognosis.
More Related Videos
11:00Multiplex Cytokine Profiling of Stimulated Mouse Splenocytes Using a Cytometric Bead-based Immunoassay Platform
Published on: November 9, 2017
12:58Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
Published on: May 10, 2017